Amgen Ventures
VC Fund
San Francisco, United States
Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, and cardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.
- Total investments:
- 121
- Last investment:
- Lead investor:
- 12%
- Fund size:
- $100M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Amgen Ventures invests in
Stages Amgen Ventures invests in
Countries Amgen Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $4.4M–$53M
- Series B
- $8.5M–$114M
- Series C
- $19M–$80M
Investment Focus
Industry
- Biotechnology 67 (55%)
- Health Care 52 (43%)
- Therapeutics 31 (26%)
- Medical 24 (20%)
- Pharmaceutical 16 (13%)
Stage
- Series B 31 (26%)
- Series A 27 (22%)
- Series C 16 (13%)
- Seed 6 (5%)
- Funding Round 6 (5%)
Country
- United States 65 (54%)
- Canada 3 (2%)
- United Kingdom 3 (2%)
- Israel 2 (2%)
- Singapore 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Suzanne Blaug
SVP, Global Marketing and Commercial Development
|
SVP, Global Marketing and Commercial Development | Total investments: 0 | Find email | |
Philip Tagari
VP Research
|
VP Research | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology. | $135M / Series B / Oct 13, 2026 | ||
| BigHat is a developer of an AI-guided protein therapeutic platform used to integrate antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatmentsfor patients suffering from today’s most challenging diseases. | $75M / Series C / Sep 24, 2026 | ||
| TileDB is foundational software designed by scientists for scientific discovery.TileDB structures all data types, including that data that does not fit into relational databases built for structured tabular data. Built on a powerful shape-shifting array database, TileDB handles the complexities of non-traditional “unstructured” multimodal data,such as genomic variants, bulk and single-cell transcriptomics, proteomics, biomedical imaging, as well as the frontier data of the future.Used by science and data teams within big pharma and biotechs to power their multiomic FAIR data platforms, TileDB is the destination for scientific breakthroughs where frontier multimodal data is driving drug discovery. | Venture - Series Unknown / Sep 16, 2026 | ||
| Ember LifeSciences is a healthcare technology company that develops cold chain solutions to support the safe transport of temperature-sensitive medicines, vaccines, and biologics using proprietary temperature control systems. The company’s core offering includes the Ember Cube. This self-refrigerated and cloud-connected shipping container providescontinuous temperature monitoring, GPS tracking, and real-time data reporting to maintain drug efficacy during transit. Ember LifeSciences leverages its engineering expertise in thermal management and digital monitoring to develop modular shipping solutions that can replace traditional single-use cold chain packaging, thereby reducing waste. It works with pharmaceutical distributors, specialty pharmacies, and laboratories by enabling visibility and control over critical environmental conditions throughout distribution. The company continues to develop next-generation versions of its devices, incorporating improved insulation and configurable features to support broader supply chain use cases. | Series A / May 27, 2026 | ||
| EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will targetimproving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). | Venture - Series Unknown / Sep 03, 2024 | ||
| Mindset Medical is a Health Care Company that develops a platform for clinical information. Through their platform physicians will understand patient pain, saves time for providers and patients, they eliminate paper and redundant forms, and allows providers more time for patients. Mindset Medical was founded in 2016 in Phoenix, Arizona. | $8M / Series A / Jun 01, 2024 | ||
| Enlaza Therapeutics is a biotechnology research company. It was founded in 2020 and is headquartered in La Jolla, California. | $100M / Series A / Apr 30, 2024 | ||
| Culmination Bio is a startup that is developing a disease-independent patient data intelligence platform. | $10M / Series A / Nov 30, 2023 | ||
| Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle. | $16.5M / Series B / Jun 13, 2023 | ||
| Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomalstorage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs. | $46M / Series C / Nov 15, 2022 | ||
| See all 121 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Amgen Ventures invest in?
Amgen Ventures invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 121 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Amgen Ventures invest in?
Amgen Ventures typically joins rounds of $4.4M–$53M at Series A, $8.5M–$114M at Series B and $19M–$80M at Series C. These are whole funding-round sizes, not Amgen Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Amgen Ventures took part in.
How do I contact Amgen Ventures?
Public channels for Amgen Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Amgen Ventures?
The team at Amgen Ventures includes Suzanne Blaug (SVP, Global Marketing and Commercial Development) and Philip Tagari (VP Research). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
